Anzeige
Mehr »
Login
Donnerstag, 27.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Jerusalem Post: Eine große Hürde für den CBD-Pharmabereich wurde von InnoCan Pharma eingerissen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XAEB ISIN: FR0011648971 Ticker-Symbol: 2QG 
Stuttgart
26.01.22
17:23 Uhr
3,690 Euro
+0,006
+0,16 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
QUANTUM GENOMICS SAS Chart 1 Jahr
5-Tage-Chart
QUANTUM GENOMICS SAS 5-Tage-Chart
RealtimeGeldBriefZeit
3,7303,75026.01.

Aktuelle News zur QUANTUM GENOMICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.12.21Quantum Genomics signs license and production agreement with Julphar1
06.12.21Quantum Genomics inks licensing nd production deal for firibastat-
06.12.21Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar-
QUANTUM GENOMICS Aktie jetzt für 0€ handeln
06.12.21QUANTUM GENOMICS: Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.533Press release Paris, December 6, 2021 Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar. Quantum Genomics will receive up to $20...
► Artikel lesen
25.11.21QUANTUM GENOMICS: Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.1.223Press release Paris, November 25, 2021 Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd. Quantum Genomics will receive up to $11 M in payments and 25% minimum up to...
► Artikel lesen
25.11.21Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.27
23.11.21QUANTUM GENOMICS: Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences224Press release Paris, November 23, 2021 Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF)...
► Artikel lesen
07.10.21QUANTUM GENOMICS: Quantum Genomics and its partners reach a new stage of development in Asia393Quantum Genomics and its partners reach a new stage of development in Asia The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and...
► Artikel lesen
07.10.21Quantum Genomics and its Partners Reach a New Stage of Development in Asia2
06.10.21QUANTUM GENOMICS: Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity333Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity Firibastat expected to launch in late 2023 for difficult-to-treat/resistant hypertension. Gross cash of €24.9...
► Artikel lesen
09.09.21Quantum Genomics - Phase IIb QUORUM results235Quantum Genomics has reported the results of the Phase IIb QUORUM study at the European Society of Cardiology. Unfortunately, the primary endpoint of change from baseline in the left ventricular ejection...
► Artikel lesen
01.09.21XFRA 2QG: WIEDERAUFNAHME/RESUMPTION156FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
27.08.21XFRA 2QG: AUSSETZUNG/SUSPENSION181DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL QUANTUM GENOMICS...
► Artikel lesen
27.08.21QUANTUM GENOMICS: Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting301Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting Firibastat is as efficent as the current standard of...
► Artikel lesen
27.08.21Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting5
13.07.21Edison Investment Research Limited: Quantum Genomics (ALQGC): Potentially Transformational Data in August321LONDON, UK / ACCESSWIRE / July 13, 2021 / Phase IIb data from the QUORUM study in heart failure (HF) patients will be presented at the European Society of Cardiology meeting, which will be held virtually...
► Artikel lesen
12.07.21Quantum Genomics - Potentially transformational data in August242Phase IIb data from the QUORUM study in heart failure (HF) patients will be presented at the European Society of Cardiology meeting, which will be held virtually from 27-30 August. If positive, we believe...
► Artikel lesen
08.07.21QUANTUM GENOMICS: Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension with Once-a-day Formulation of Firibastat.250Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and...
► Artikel lesen
05.07.21QUANTUM GENOMICS: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology261Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant high...
► Artikel lesen
28.06.21QUANTUM GENOMICS: QUORUM study: Results Announcement next August 27, 2021 at 10:30 am CEST303Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1